Immunotherapy News and Research

Latest Immunotherapy News and Research

Researchers identify effective way to protect vulnerable people from COVID-19

T-cells taken from the blood of people who recovered from a COVID-19 infection can be successfully multiplied in the lab and maintain the ability to effectively target proteins that are key to the virus's function, according to a new study published Oct. 26 in Blood.

27 Oct 2020

Multimodal mapping of immune landscape in pancreatic cancer could guide personalized therapies

Pancreatic cancer has remained resistant to immunotherapies that are revolutionizing the treatment of many types of cancer.

27 Oct 2020

Study better reveals the function and behavior of macrophages in cancer growth

Macrophages, cells that help engulf and destroy harmful organisms in the body, tend to be characterized as the Jekyll and Hyde of the immune system.

27 Oct 2020

Mathematical modeling study offers new insights into optimal timing of antiviral therapies against COVID-19

A new mathematical modeling study by Ashish Goyal and colleagues, informed by data collected from 25 patients hospitalized with COVID-19 in 4 different countries, offers some important new insights into the optimal timing of 4 different antiviral therapies to combat the disease.

23 Oct 2020

New technique could propel personalized cancer treatments

When it comes to defeating cancer, some immune cells are mightier than others. But even the best-trained eye and today's advanced scientific tools have trouble discerning the most powerful tumor-fighting cells from the rest.

23 Oct 2020

Study: Antibody-based drug could dramatically reduce cancer in mice

Despite the remarkable successes of immune-based treatments for cancer, not everyone responds to these approaches and relapses do occur.

22 Oct 2020

Ancient elements in human DNA can activate powerful immune response to kill cancer cells

Ancient embedded elements in our DNA from generations past can activate a powerful immune response to kill cancer cells like an infection.

22 Oct 2020

Moffitt researchers find immune-oncologic differences in prostate tumors of African American men

Prostate cancer is the most common type of cancer among American men after skin cancer, but the disease does not affect all races equally.

21 Oct 2020

New vaccine targeting toxic Aβ may offer clinical benefit in treating Alzheimer's disease

Our immune system's capacity to mount a well-regulated defense against foreign substances, including toxins, weakens with age and makes vaccines less effective in people over age 65.

20 Oct 2020

Novel microfluidic approach to fight cancer could greatly benefit patients

CAR-T biotherapeutics company Carina Biotech and researchers at the University of South Australia have developed a novel approach based on microfluidic technology to "purify" the immune cells of patients in the fight against cancer.

20 Oct 2020

UCLA professor named to the National Academy of Medicine

Dr. Antoni Ribas, a world-renowned physician-scientist and professor of medicine at the David Geffen School of Medicine at UCLA, has been named to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.

19 Oct 2020

Cell nucleus may play role in enabling cells to evade crowded environments

Like people, cells in the human body protect their personal space. They seem to know how much space they need, and if it gets too tight, most cells prefer to break free.

19 Oct 2020

New tool can provide non-invasive decision support for NSCLC treatment

Personalized treatment options for patients with lung cancer have come a long way in the past two decades.

16 Oct 2020

Key blood marker can lead to effective melanoma treatments

An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.

16 Oct 2020

Patients with soft-tissue cancer show rapid and complete response to novel combination of immunotherapy

A patient with end-stage and rapidly progressing soft-tissue cancer whose tumor did not respond to standard treatment, had a "rapid and complete response" to a novel combination of immunotherapy, according to new research published by a team of scientists from John Theurer Cancer Center at Hackensack University Medical Center and the Georgetown Lombardi Comprehensive Cancer Center, both of whom are part of the Georgetown Lombardi Comprehensive Cancer Center Consortium.

16 Oct 2020

CAR NKT cells offer a promising approach to combat hard-to-treat solid tumors

Natural killer T (NKT) cells, a type of immune cells known for their potent anti-cancer properties in murine tumor models, have been developed into a novel form of immunotherapy to treat patients with cancer.

13 Oct 2020

Neoadjuvant trial of combination immunotherapy has favorable outcomes in bladder cancer patients

Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1) was well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who do not have standard treatment options available, according to a Phase I clinical trial conducted by The University of Texas MD Anderson Cancer Center.

13 Oct 2020